^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    budigalimab (ABBV-181)

    i
    Other names: ABBV-181, ABBV 181, ABBV181
    Company:
    AbbVie
    Drug class:
    PD1 inhibitor
    Related drugs:
    6d
    A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 (clinicaltrials.gov)
    P2, N=140, Recruiting, AbbVie | Trial completion date: Nov 2025 --> Oct 2026
    Trial completion date • Adverse events
    |
    CD4 (CD4 Molecule)
    |
    budigalimab (ABBV-181)
    8d
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=362, Recruiting, AbbVie | Trial primary completion date: Feb 2026 --> Jun 2027
    Trial primary completion date • Combination therapy • Metastases
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    17d
    TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=185, Completed, Trishula Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • gemcitabine • docetaxel • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • budigalimab (ABBV-181) • leucovorin calcium • TTX-030
    24d
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, AbbVie | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025
    Trial completion date • Trial primary completion date • Adverse events • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type • SEZ6 expression
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    1m
    LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=840, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    1m
    Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)
    P2, N=180, Recruiting, Trishula Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Mar 2024
    Enrollment open • Trial initiation date • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • TTX-030
    1m
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=337, Recruiting, AbbVie | Trial completion date: Feb 2026 --> Jun 2027
    Trial completion date • Combination therapy • Metastases
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    2ms
    LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=840, Not yet recruiting, AbbVie
    New P2/3 trial • Adverse events • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    3ms
    A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=132, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion
    |
    SEZ6 (Seizure Related 6 Homolog)
    |
    budigalimab (ABBV-181) • ABBV-011
    3ms
    A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=181, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    budigalimab (ABBV-181)
    4ms
    LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3
    Enrollment open • Phase classification • Adverse events • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    5ms
    A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=181, Not yet recruiting, AbbVie
    New P1 trial • Adverse events • Combination therapy • Pan tumor • Metastases
    |
    budigalimab (ABBV-181)
    6ms
    Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Trishula Therapeutics, Inc.
    New P2 trial • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • TTX-030
    6ms
    LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2, N=660, Not yet recruiting, AbbVie
    New P2 trial • Adverse events • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    6ms
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=337, Recruiting, AbbVie | Trial completion date: Apr 2024 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    6ms
    A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 (clinicaltrials.gov)
    P2, N=140, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    CD4 (CD4 Molecule)
    |
    budigalimab (ABBV-181)
    9ms
    Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors (ESMO 2023)
    The study will evaluate the preliminary safety, tolerability, pharmacokinetics (PK), and antitumor activity of ABBV-706 as monotherapy and in combination with budigalimab (a PD-1 inhibitor), carboplatin, or cisplatin, and determine the recommended phase 2 dose (RP2D) of ABBV-706. Tumor tissue submission for retrospective SEZ6 expression analysis is required. The study began in December 2022 and enrollment is ongoing.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    SEZ6 (Seizure Related 6 Homolog)
    |
    SEZ6 expression
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    9ms
    First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors (ESMO 2023)
    In dose expansion, patients with R/R non-small cell lung cancer will be enrolled in ABBV-514 monotherapy (N=12) and ABBV-514 + BDG (N=12) cohorts, and patients with R/R head and neck squamous cell carcinoma in an ABBV-514 + BDG (N=12) cohort. Enrollment initiated in November 2021, with 30 patients enrolled as of April 2023.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    budigalimab (ABBV-181) • ABBV-514
    10ms
    Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis (clinicaltrials.gov)
    P1b/2, N=129, Recruiting, AbbVie | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Adverse events • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • budigalimab (ABBV-181) • leucovorin calcium • giloralimab (ABBV-927)
    11ms
    A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=132, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=233 --> 132
    Enrollment closed • Enrollment change • Combination therapy
    |
    budigalimab (ABBV-181) • ABBV-011
    1year
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    over1year
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    over1year
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Not yet recruiting, AbbVie
    New P1 trial • Adverse events • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    over1year
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | Trial completion date: Jul 2024 --> Nov 2023
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    almost2years
    Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. (PubMed, Ann Oncol)
    We demonstrate that baseline ARG levels predict ICI response. Plasma ARG quantification may therefore represent an attractive biomarker to tailor novel therapeutic regimens targeting the ARG pathway in combination with ICIs.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    budigalimab (ABBV-181)
    almost2years
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | Trial completion date: Dec 2023 --> Jul 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    almost2years
    A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=139, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    budigalimab (ABBV-181) • revdofilimab (ABBV-368)
    2years
    A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=182, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Venclexta (venetoclax) • budigalimab (ABBV-181) • Rova-T (rovalpituzumab tesirine)
    2years
    Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer (AACR 2022)
    The addition of nivolumab to chemotherapy has recently become the standard of care of 1st‑line (1L) treatment of locally advanced or metastatic (LA/M) gastric cancer but further improvements are needed. An expansion cohort of Study TTX‑030‑002 (ongoing, US and South Korea) is evaluating the safety and efficacy of the combination of TTX-030, budigalimab (anti-PD-1) and FOLFOX for the 1L treatment of patients (pts) with LA/M HER2− gastric/GEJ adenocarcinoma... Preliminary results indicate that the combination of TTX-030, budigalimab and FOLFOX exhibited promising efficacy as 1L treatment of LA/M gastric/GEJ cancer regardless of CPS status and has a manageable safety profile without evidence of excessive toxicities. To our knowledge, this represents the first report of an anti-CD39 antibody in combination with chemo-immunotherapy in gastric cancer. Updated clinical and biomarker data will be included in the final presentation.
    Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Opdivo (nivolumab) • 5-fluorouracil • budigalimab (ABBV-181) • leucovorin calcium • TTX-030
    2years
    A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=170, Active, not recruiting, AbbVie | Trial completion date: Sep 2021 --> Feb 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    budigalimab (ABBV-181) • revdofilimab (ABBV-368)
    over2years
    Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. (PubMed, J Immunother)
    Univariate analysis demonstrated an association between prolonged progression-free survival and higher tumor mutational burden/neoantigen load, smaller tumor size, lower platelet-lymphocyte ratios, lower CCL23, lower colony-stimulating factor 1, and lower interleukin-6 levels at baseline. The biomarker analysis presented herein identified additional early pharmacodynamic biomarkers associated with anti-PD-1 activity and improved clinical responses to budigalimab in patients with advanced HNSCC and NSCLC.
    Clinical • PK/PD data • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CSF1 (Colony stimulating factor 1)
    |
    PD-L1 expression • IL6-L
    |
    budigalimab (ABBV-181)
    over2years
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab (clinicaltrials.gov)
    P1, N=136, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514
    over2years
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, AbbVie | N=184 --> 260 | Trial primary completion date: Jul 2022 --> Apr 2023
    Clinical • Enrollment change • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • PGR negative
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    over2years
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=184, Recruiting, AbbVie | Trial completion date: Jul 2022 --> Apr 2023
    Clinical • Trial completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • PGR negative
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    over2years
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab (clinicaltrials.gov)
    P1, N=136, Not yet recruiting, AbbVie
    Clinical • New P1 trial • Adverse events • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514
    over2years
    Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. (PubMed, Cancer Treat Res Commun)
    Combination therapy with budigalimab and Rova-T had promising efficacy and appeared to be tolerated in patients with SCLC. Although Rova-T development has been discontinued, development of budigalimab combined with other anticancer agents is ongoing.
    Clinical • PK/PD data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    budigalimab (ABBV-181) • Rova-T (rovalpituzumab tesirine)
    almost3years
    First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. (PubMed, Cancer Immunol Immunother)
    The safety, efficacy and biomarker profiles of budigalimab are similar to other PD-1 inhibitors. Development of budigalimab in combination with novel anticancer agents is ongoing.
    Clinical • P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    PD-L1 expression
    |
    budigalimab (ABBV-181)
    almost3years
    A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=182, Active, not recruiting, AbbVie | Trial completion date: Mar 2021 --> May 2022 | Trial primary completion date: Mar 2021 --> May 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Venclexta (venetoclax) • budigalimab (ABBV-181) • Rova-T (rovalpituzumab tesirine)
    over3years
    A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, AbbVie | Trial primary completion date: May 2023 --> Nov 2023
    Clinical • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PD-L1 negative
    |
    carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
    over3years
    A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Jan 2021 --> Sep 2021
    Clinical • Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    budigalimab (ABBV-181) • revdofilimab (ABBV-368)
    over3years
    A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=221, Recruiting, AbbVie | Trial primary completion date: Sep 2021 --> Dec 2021
    Clinical • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Venclexta (venetoclax) • budigalimab (ABBV-181) • Rova-T (rovalpituzumab tesirine)
    almost4years
    [VIRTUAL] Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours (ESMO 2020)
    Funding: AbbVie Inc. Clinical trial identification: NCT03821935.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)